Tesamorelin

Base Peptides are intended for licensed medical professionals and experienced researchers. Reconstitution required. Dosing and use instructions are not provided.

$90.00

Sale Sold out

Shipping calculated at checkout.

Quantity Single Vial 5 Vial Package 10 Vial Package

Quantity

Tesamorelin — Research-Grade GHRH Analogue

Tesamorelin is a stabilized version of the body’s own GHRH signal. In research, it’s used to nudge the growth-hormone (GH) system to work naturally—so labs can study changes in IGF-1, visceral fat (VAT), liver fat, and metabolic markers without using direct GH.

Identifiers

CAS: 218949-48-5
PubChem CID: 146681838
Formula / MW: C₂₂₁H₃₆₆N₇₂O₆₇S · ~5,135.8 Da
Sequence: GHRH(1-44) analogue with an N-terminal stabilization (trans-3-hexenoic acid)

How It Works (Plain English)

Tesamorelin binds the same receptor your natural GHRH uses.
That signals the pituitary to release GH in a physiologic, pulse-like way.
GH then raises IGF-1, which is tied to how the body handles fat and lean tissue.

Why Researchers Use It

To study visceral fat (VAT) changes measured by CT or MRI.
To observe liver fat changes with MR-spectroscopy.
To map GH → IGF-1 signaling without giving GH directly.

Key Studies — What Was Tested, What Changed, Why It Matters

Two large randomized trials in people with HIV on ART (excess VAT)

Design, in brief: Daily 2 mg tesamorelin vs placebo for 26 weeks; some continued to 52 weeks.
What changed: About a 15% drop in visceral fat vs placebo at 26 weeks. Those who continued generally kept the benefit at 52 weeks. Subcutaneous fat was mostly preserved.
Why it matters: Tesamorelin helps researchers isolate visceral fat changes—important because VAT is more strongly linked to metabolic risk than the fat under the skin.
Context signals tracked: IGF-1, triglycerides, and glucose markers for a fuller metabolic picture.

VAT + Liver fat (6-month double-blind study with imaging)

Design, in brief: Randomized, placebo-controlled, 6 months.
What changed: Significant VAT reduction and a modest decrease in liver fat (measured by MR-spectroscopy).
Why it matters: Supports the idea that restoring a healthier GH/IGF-1 rhythm can favor how and where the body stores fat—especially in the liver.

Who tends to respond better? (predictor analysis)

Design, in brief: Post-study analysis of the big trials.
Signal: People with higher starting VAT or features of metabolic syndrome often showed larger VAT improvements.
Why it matters: Helps labs pre-define responder groups and stratify subjects up front.

Potential Research Applications

Metabolic & Adipose Biology

CT/MRI VAT quantification
Triglycerides, adipokines, inflammation panels

Liver & Ectopic Fat

MR-spectroscopy liver fat fraction
Protocol-dependent NAFLD-style models

GH/IGF-1 Axis Mapping

IGF-1 kinetics, binding proteins, pulse analysis
Downstream signaling and tissue markers

Synergistic Peptides (for Study Design)

CJC-1295 (with DAC)

What it is: A long-acting GHRH analogue (prolonged effect).
Why pair it: Useful in duration or frequency studies comparing short- vs long-acting GHRH-style signals.
Typical research angle: IGF-1 exposure over time, pulse patterns, and body-composition markers.

Ipamorelin (GHSR agonist)

What it is: A selective ghrelin-receptor (GHSR) agonist—a different upstream switch for GH.
Why pair it: Lets labs explore dual-pathway stimulation (GHRH + GHSR) vs either alone.
Typical research angle: Additive or complementary GH release, IGF-1 response, and downstream markers.

Sermorelin / Mod GRF (1-29)

What it is: Short-acting GHRH-type analogues.
Why pair it: Good for timing experiments (short pulses) or as a comparator to longer-acting analogues like Tesamorelin or CJC-1295.
Typical research angle: Pulse frequency vs amplitude studies; receptor sensitivity.

Design Notes

Keep groups clearly separated (GHRH-only vs GHSR-only vs combo).
Pre-define endpoints: IGF-1 time-course, VAT change on imaging, lipid/glucose panels.
Document timing relative to sampling to interpret pulses accurately.

Known Concerns (Context)

Glucose: Some studies note small, temporary rises in fasting glucose—track per protocol.
Common observations: Injection-site reactions, mild joint swelling, or fluid retention have been reported in labeled contexts.
Program scope: Tesamorelin isn’t a general weight-loss agent; it’s best suited to VAT-focused and mechanistic research questions.

Follow your institution’s SOPs and oversight (IRB/IBC) for handling and design.

Specifications & Handling

Form: Lyophilized powder (lot-coded)
Purity: ≥ 99% (HPLC/MS; lot-verified)
Storage: ≤ −20 °C; protect from light and moisture

In solution: Aliquot promptly; avoid repeat freeze–thaw
Additives: None unless specified on the lot
Packaging: Tamper-evident; research-only labeling

Regulatory & Use Notice

Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance.

Tesamorelin Peptide Research | GHRH Analogue | Visceral Fat (VAT), Liver Fat & IGF-1 Studies

Keywords: Tesamorelin peptide, GHRH analogue, visceral adipose tissue research, VAT imaging CT MRI, IGF-1 kinetics, liver fat MR-spectroscopy, GH axis studies, Base Peptides.

View full details

Instructions are NOT provided before or after purchase.

Peptide molecules are unfinished and require reconstitution from a skilled and licensed professional to activate the compound into liquid form. Instructions are not provided for reconstitution, dosing, or adminstration. All products are strictly intended for research purposes and laboratory experimentation. Handling should be by skilled licensed and credentialed professionals only. Non experimental use is strictly prohibited.

Keep Shopping